Actively Recruiting
A Study on Efficacy and Safety of HST101 in Chinese Patients with Hypercholesterolemia
Led by Hasten Biopharmaceutical Co., Ltd. · Updated on 2025-02-06
210
Participants Needed
18
Research Sites
75 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
This randomized study is to assess LDL-C reductions at Week 12 with monthly (Q4W \[≤31 days\]) dosing of HST101 (lerodalcibep) 300 mg administered subcutaneously (SC) compared to placebo in patients with atherosclerotic cardiovascular disease (ASCVD) or very-high/high risk for ASCVD including Heterozygous familial hypercholesterolemia (HeFH) on a stable diet and oral LDL-C lowering drug therapy, followed by 36-week open-label treatment with subsequent 4-week follow-up for total 52-week long-term safety and efficacy evaluation.
CONDITIONS
Official Title
A Study on Efficacy and Safety of HST101 in Chinese Patients with Hypercholesterolemia
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Provision of written and signed informed consent form prior to any study-specific procedure;
- Male or female participants ≥18 years of age at the screening visit;
- Body weight ≥ 40 kg and body mass index (BMI) ≥18 and ≤35 kg/m2;
- On a stable diet and lipid-lowering oral drugs (such as statins, ezetimibe or Hybutimibe, omega-3 compounds, fenofibrate, nicotinic acid, etc.) for at least 4 weeks prior to the first drug administration
- LDL-C≥1.8 mmol/L (70 mg/dL) and TG≤4.52 mmol/L (400 mg/dL) at screening for ASCVD patients or those at very (ultra)-high risk for ASCVD, including patients with HeFH; LDL-C ≥ 2.6 mmol/L (100 mg/dL) and TG ≤ 4.52 mmol/L (400 mg/dL) at screening for patients at high-risk for ASCVD including patients with HeFH;
- Patients on a PCSK9 mAb at a dose of 75 mg, 140 mg, or 150 mg Q2W must undergo a washout period of ≥6 weeks after the last dose; for those on 300 mg or 420 mg Q4W, the washout period is ≥10 weeks following last dose;
- Female of childbearing potential must have a negative pregnancy test at the last screening visit and consent to use highly effective contraceptives during the trial and 3 months after the last dose of investigational drug.
You will not qualify if you...
- Documented history of homozygous familial hypercholesterolemia (HoFH);
- Estimated glomerular filtration rate (eGFR)<30 mL/min/1.73m2;
- Active liver disease or hepatic dysfunction, history of liver transplant, and/or ALT or AST >2.5 × ULN at screening;
- Poorly controlled thyroid disorder including hypothyroidism or hyperthyroidism;
- Poorly controlled Type 1 or Type 2 diabetes mellitus defined as fasting blood glucose ≥11.0 mmol/L (200 mg/dL) and glycosylated hemoglobin (HbA1c) ≥ 9%;
- Serious arrhythmia, MI, unstable angina pectoris, PCI, CABG, implantable cardioverter defibrillator, aortic valve surgery or stroke within 3 months prior to the first dose;
- Planned cardiac surgery or revascularization during the study period;
- New York Heart Association (NYHA) Class III-IV heart failure;
- Pregnant or lactating women;
- Poorly controlled hypertension (SBP≥160 mmHg or DBP≥100 mmHg in a sitting position)
- Unexplained creatine kinase (CK) > 5 x ULN (retested once is needed if suspected to be related to excessive exercise or abnormal activity);
- LDL apheresis or plasma exchange within 2 months prior to the first dose;
- HIV, Treponema pallidum, or HCV antibody test positive, or HBV-DNA >ULN at screening;
- History of prescription drug abuse, illicit drug use or alcohol abuse within 6 months prior to screening;
- History of any major drug allergy, including allergy to protein biologics;
- Participate another clinical trial within 30 days or less than 5 half-lifes (drug) before screening, whichever is longer
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 18 locations
1
Beijing Anzhen Hospital of Capital Medical University
Beijing, Beijing Municipality, China
Actively Recruiting
2
Beijing Luhe Hospital, Capital Medical Univeristy
Beijing, Beijing Municipality, China
Actively Recruiting
3
Beijing Tsinghua Changgeng Hospital
Beijing, Beijing Municipality, China
Actively Recruiting
4
Fuwai Hospital, CAMS & PUMC
Beijing, Beijing Municipality, China
Actively Recruiting
5
Guangdong Provincial People's Hospital
Guangzhou, Guangdong, China
Actively Recruiting
6
Shijiazhuang People's Hospital
Shijiazhuang, Hebei, China
Actively Recruiting
7
Daqingshi People's Hospital
Daqing, Heilingjiang, China
Actively Recruiting
8
The 2nd Xiangya Hospital of Central South University
Changsha, Hunan, China
Actively Recruiting
9
The Third Xiangya Hospital of Central South University
Changsha, Hunan, China
Actively Recruiting
10
Nanchang People's Hospital
Nanchang, Jiangxi, China
Actively Recruiting
11
Binzhou Medical University Hospital
Binzhou, Shandong, China
Actively Recruiting
12
Heze Municipal Hospital
Heze, Shandong, China
Actively Recruiting
13
Qilu Hospital of Shandong University
Jinan, Shandong, China
Actively Recruiting
14
Zibo Municipal Hospital
Zibo, Shandong, China
Actively Recruiting
15
West China Hospital of Sichuan University
Chengdu, Sichuan, China
Actively Recruiting
16
Tianjin People's Hospital
Tianjin, Tianjin Municipality, China
Actively Recruiting
17
The First Affiliated Hospital of Wenzhou Medical Univesity
Wenzhou, Zhejiang, China
Actively Recruiting
18
Peking University First Hospital
Beijing, China, 100034
Not Yet Recruiting
Research Team
Y
Yong Huo
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
TRIPLE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here